Literature DB >> 33001351

Diagnostic accuracy of the Berlin questionnaire and therapeutic effect of nasal continuous positive airway pressure in OSAHS patients with glucose metabolic dysfunction.

Lin-Jing Gong1, Su-Chi Chang1,2,3, Qin-Han Wu1,3, Zi-Long Liu1,3, Xu Wu4,5, Shan-Qun Li6,7.   

Abstract

PURPOSE: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is associated with alterations in glucose metabolism. The Berlin questionnaire (BQ) is effective in identifying subjects with high risk of OSAHS. However, its validity in patients with glucose metabolic dysfunction remains unclear. Our study aims to examine the diagnostic efficacy of the BQ in detecting OSAHS in patients with glucose metabolic dysfunction and to explore the effect of nasal CPAP on glucose metabolism.
METHODS: Patients with glucose metabolic dysregulation were first asked to complete the BQ and then recruited for polysomnogram (PSG). The diagnostic accuracy of the BQ and the relationships between groups with normal glucose tolerance (NGT), elevated fasting blood glucose (IFG), impaired glucose tolerance (IGT), and diabetes mellitus (DM) were analyzed. Subjects with both OSAHS and glucose dysregulation received CPAP treatment and underwent an oral glucose tolerance test. Changes in apnea-hypopnea indices (AHI) and glycemic parameters were calculated to determine the efficacy of CPAP.
RESULTS: Glycosylated hemoglobin and insulin levels were statistically different between the high-risk and low-risk groups according to the BQ. For diagnosis of subjects with OSAHS who also had glucose metabolic dysfunction, the sensitivity and specificity of the BQ using AHI cut-off values at 5 events per hour were 73% and 67%. CPAP therapy effectively reduced the blood glucose, HOMA-IR, and insulin levels.
CONCLUSIONS: The BQ can be considered to be an effective and economical screening tool for patieints with OSAHS who also have glucose metabolic dysfunction. Treatment with CPAP may improve glycemic parameters.

Entities:  

Keywords:  Berlin questionnaire (BQ); Continuous positive airway pressure therapy (CPAP); Glucose metabolic dysfunction; Obstructive sleep apnea–hypopnea syndrome (OSAHS)

Mesh:

Substances:

Year:  2020        PMID: 33001351     DOI: 10.1007/s11325-020-02198-8

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  2 in total

1.  Obstructive sleep apnea and incident type 2 diabetes.

Authors:  Mako Nagayoshi; Naresh M Punjabi; Elizabeth Selvin; James S Pankow; Eyal Shahar; Hiroyasu Iso; Aaron R Folsom; Pamela L Lutsey
Journal:  Sleep Med       Date:  2016-09-29       Impact factor: 3.492

2.  Risk of obstructive sleep apnea in patients with type 2 diabetes mellitus.

Authors:  Alvah R Cass; W Jerome Alonso; Jamal Islam; Susan C Weller
Journal:  Fam Med       Date:  2013 Jul-Aug       Impact factor: 1.756

  2 in total
  2 in total

1.  NLRP3 Deficiency Protects Against Intermittent Hypoxia-Induced Neuroinflammation and Mitochondrial ROS by Promoting the PINK1-Parkin Pathway of Mitophagy in a Murine Model of Sleep Apnea.

Authors:  Xu Wu; Linjing Gong; Liang Xie; Wenyu Gu; Xinyuan Wang; Zilong Liu; Shanqun Li
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

2.  Changes of circulating biomarkers of inflammation and glycolipid metabolism by CPAP in OSA patients: a meta-analysis of time-dependent profiles.

Authors:  Yi Wang; Ying Ni Lin; Li Yue Zhang; Chuan Xiang Li; Shi Qi Li; Hong Peng Li; Liu Zhang; Ning Li; Ya Ru Yan; Qing Yun Li
Journal:  Ther Adv Chronic Dis       Date:  2022-05-01       Impact factor: 4.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.